对阿尔茨海默病的胆固醇修饰策略:承诺还是谬误?
Katia Azarfar1, Boris Decourt1, Brandon Sanchez Camacho2
1Department of Pharmacology and Neurosciences, Texas Tech University Health Sciences Center, Lubbock, TX, USA.
Expert review of neurotherapeutics
|March 27, 2025
概括
胆固醇影响阿尔茨海默病 (AD) 的发展. 胆固醇修饰疗法可能有利于早期的AD,但不太可能帮助中度或晚期的AD,为AD患者的高胆固醇血症管理提供了建议.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生化学
- 老年学是一门学科.
背景情况:
- 阿尔茨海默病 (AD) 患病率随着全球人口老龄化而增加.
- 胆固醇在AD病因和进展中的确切作用仍在调查中.
- 现有证据表明胆固醇和AD病原体之间存在联系,但胆固醇修饰策略的临床应用仍然不确定.
研究的目的:
- 审查胆固醇在阿尔茨海默病中的作用.
- 总结关于阿尔茨海默病的胆固醇修饰疗法的临床前和临床证据.
- 为AD患者管理高胆固醇血症提供建议.
主要方法:
- 对从1990年到2024年的研究进行了PubMed的综合文献搜索.
- 该评论包括对胆固醇代谢的概述.
- 总结了关键的临床前研究和临床试验,涉及AD中的胆固醇修饰疗法.
主要成果:
- 流行病学和机理学数据表明,胆固醇可能有助于AD病因.
- 胆固醇修饰疗法对预症状到早期AD阶段的治疗有希望.
- 这些疗法不太可能在AD的后期阶段有效.
结论:
- 胆固醇与阿尔茨海默病的发展有关.
- 早期干预胆固醇修饰治疗可能是有益的.
- 讨论了阿尔茨海默病患者高胆固醇血症的管理策略.
相关概念视频
Alzheimer's Disease: Treatment
137
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
137
Alzheimer's Disease: Overview
399
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
399
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
86
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
86
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
484
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
484
Role of Neurotransmitters in Memory
351
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
351
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
588
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
588


